KPT 9274 ( ATG-019) 是一种具有口服活性的小分子化合物，是非竞争性的PAK4和NAMPT双重抑制剂。在cell-free的酶活实验中，对NAMPT的IC50值约为120 nM。 Information KPT 9274 ( ATG-019) KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT . It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay. Targets PAK4 (Cell-free assay); NAMPT (Cell-free assay) ; ~120 nM In vitro KPT-9274 interferences with PAK4 and NAD biosynthetic pathways results in reduction of G2/M transit as well as induction of apoptosis and decrease in cell invasion and migration in several human RCC cell lines. The inhibition of the PAK4 pathway by KPT-9274 attenuates nuclear β-catenin as well as the Wnt/β-catenin targets cyclin D1 and c-Myc. In vivo KPT-9274 administration to a 786-O (VHL-mut) human RCC xenograft model leads to dose-dependent inhibition of tumor growth with no apparent toxicity. It also shows remarkable anti-tumor activity in sub-cutaneous xenograft models of pancreatic ductal adenocarcinoma (PDAC) cell lines and cancer stem cells as a single agent. KPT-9274 possesses desirable PK properties and is well tolerated in mice with the absence of any signs of toxicity when 200 mg/kg daily is administered either intravenously or orally. Cell Research(from reference) Cell lines：786-0, ACHN, Caki-1 and U-2 OS cells Concentrations：1μM and 5μM Incubation Time：12 hours